Propanc Biopharma, Inc.
For the period ended Jun 30, 2026. Filed Sep 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PROPANC BIOPHARMA, INC. | ||
| Dated: September 25, 2026 | By: | /s/ James Nathanielsz |
|---|---|---|
| James Nathanielsz | ||
| Chief Executive Officer, | ||
| (Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ James Nathanielsz | Chief Executive Office and Director | September 25, 2026 |
| James Nathanielsz | (Principal Executive Officer) | |
| /s/ Jeannine Zimmerman | Chief Financial Officer | September 25, 2026 |
| Jeannine Zimmerman | (Principal Financial Officer) | |
| /s/ Ralf Brandt | Director | September 25, 2026 |
| Ralf Brandt | ||
| /s/ Josef Zelinger | Director | September 25, 2026 |
| Josef Zelinger | ||
| /s/ Joseph Himy | Director | September 25, 2026 |
| Joseph Himy | ||
| /s/ Carlo Campiciano | Director | September 25, 2026 |
| Carlo Campiciano | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.